Oncology
Refine Search
Biotechnology
Shares of US drugmaker Summit Therapeutics went stratospheric yesterday, rocketing 194% to $2.31 by close, after it announced a licensing deal with a Chinese drug developer that could cost it as much as $5 billion. 7 December 2022
Pharmaceutical
A new collaboration in autoimmune disorders has been launched between Chicago-based AbbVie and another American company, HotSpot Therapeutics. 6 December 2022
Biotechnology
Ireland and USA-based natural killer (NK) cell therapy biotech ONK Therapeutics has named Bruce McCreedy as chief scientific officer (CSO). 6 December 2022
Biotechnology
US clinical-stage cancer focused biotech Mirati Therapeutics has announced preliminary results from the KRYSTAL-7 Phase II trial and KRYSTAL-1 Phase Ib cohort evaluating adagrasib (400mg twice daily) concurrently combined with Merck & Co’s blockbuster drug Keytruda (pembrolizumab) in patients for the treatment of first-line non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation across all PD-L1 subgroups. 6 December 2022
Biotechnology
Swiss pharma giant Novartis was up nearly 2% as Monday’s trading day neared its end in Europe. 5 December 2022
Biotechnology
Patients have been dealt a major blow after the first ever treatment for AL amyloidosis, a rare incurable condition, was rejected by the UK’s National Institute for Health and Care Excellence (NICE). 5 December 2022
Pharmaceutical
Additional data from the Phase III EMERALD study (NCT03778931) of elacestrant, an investigational oral selective estrogen receptor degrader (SERD), are being presented during the San Antonio Breast Cancer Symposium (SABCS) being held from December 6-10. 5 December 2022
Biotechnology
US clinical-stage targeted oncology company Mirati Therapeutics saw its shares close up 5.2% at $96.25 on Friday, after it announced that, based on the results of an interim analysis on overall survival (OS), the registrational Phase III study evaluating sitravatinib in combination with nivolumab (Bristol Myers Squibb’s blockbuster drug Opdivo) in patients with second or third line non-squamous non-small cell lung cancer (NSQ-NSCLC) who have acquired resistance to prior therapy with chemotherapy and immune checkpoint inhibitor therapy (SAPPHIRE) will continue to the study's final analysis. 5 December 2022
Biotechnology
The European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) for aumolertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI). 2 December 2022
Biotechnology
Shares of UK-based biotech Immunocore Holdings edged up 2.2% to $61.29 pre-market, as the company announced a collaboration with Netherlands-based Gadeta on the first γδ ImmTAC for solid tumors, including colorectal cancer. 2 December 2022
Biotechnology
Unsurprisingly given a negative advisory committee vote a few weeks ago, the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the Biologics License Application (BLA) for the investigational medicine 131I-omburtamab in the treatment of CNS/leptomeningeal metastasis from neuroblastoma, submitted by US biotech Y-mAbs Therapeutics. 2 December 2022
Biotechnology
A late comer to the PD-/PD-Li inhibitors sector, UK pharma major GSK has had a fair number of disappointments with its new cancer drugs. Just a few days ago, the company withdrew the US marketing authorization for multiple myeloma drug Blenrep (belantamab mafodotin-blmf). 2 December 2022
Pharmaceutical
Well ahead of expectations, on December 1, the US Food and Drug Administration (FDA) approved Rezlidhia (olutasidenib) capsules for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. 2 December 2022
Biotechnology
London-listed Finnish biotech firm Faron Pharmaceuticals today announces the appointment of Faron co-founder Maija Hollmén as chief scientific officer of the company. 1 December 2022
Biotechnology
Shares of Poland-based oncology specialist Ryvu Therapeutics closed up 17.7% at 51.19 zloty today, on news that the company had entered into a multi-target research collaboration with Germany’s BioNTech. 30 November 2022
Biotechnology
Although at present there are no messenger RNA (mRNA) non-vaccine therapeutics on the market, this landscape will reach a total of five marketed products by 2028, generating over $2 billion in revenue across the seven major markets (7MM), says analyst. 30 November 2022
Biotechnology
Shares of Australian clinical-stage biotech Immutep closed up 4.3% at A$0.36 today, after it announced it has signed a second clinical trial and supply agreement with Germany’s Merck KGaA and US pharma giant Pfizer. 29 November 2022
Biotechnology
Swiss pharma giant Roche has announced the voluntary withdrawal of a US indication for Tecentriq (atezolizumab), its blockbuster immuno-oncology drug. 29 November 2022
Biotechnology
Marking its third M&A deal so far this year, UK pharma major AstraZeneca today revealed it is to acquire Neogene Therapeutics. 29 November 2022
Biotechnology
Shares in Arcus Biosciences were more than 7% higher at lunchtime Monday. 28 November 2022
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze